|
62
|
169
|
9oelA |
Kras wild type 1-169 at 293 k |
|
61
|
166
|
9pvfA |
Kras complex with um0152533 compound |
|
0
|
9
|
9pvfI |
Kras complex with um0152533 compound |
|
60
|
167
|
10nuA |
Structure of kras g12c bound to inhibitor 13ab |
|
61
|
166
|
10nvA |
Structure of kras g12c bound to inhibitor 13ba |
|
59
|
169
|
9o0oA |
Crystal structure of gmppnp-bound wild type kras in complex with mrtx1133 |
|
69
|
169
|
9o0nA |
Crystal structure of gdp-bound wild type kras in complex with mrtx1133 |
|
55
|
168
|
9glzA |
Kras-g12d-gmppnp in complex with the nanobody km12-am |
|
28
|
120
|
9glzC |
Kras-g12d-gmppnp in complex with the nanobody km12-am |
|
59
|
169
|
9gbjA |
Kras g12d in complex with covalent inhibitor |
|
60
|
169
|
9ggxA |
Human kras4a (gmppnp) in complex with compound 19 |
|
56
|
169
|
9gh2A |
Human kras4a (gmppnp) in complex with compound 36 |
|
69
|
170
|
9ggvA |
Human kras4a (gdp) in complex with compound 14 |
|
71
|
169
|
9gguA |
Human kras4a (gdp) in complex with compound 9 |
|
68
|
170
|
9g0yA |
Human kras4a (gdp) in complex with compound 11 |
|
60
|
169
|
9ggwA |
Human kras4a (gdp) in complex with compound 16 |
|
69
|
169
|
9g4bA |
Human kras4a (gdp) in complex with compound 15 |
|
65
|
170
|
9ggtA |
Human kras4a (gdp) in complex with compound 8 |
|
65
|
170
|
9ggyA |
Human kras4a (gdp) in complex with compound 29 |
|
60
|
169
|
9gh1A |
Human kras4a (gmppnp) in complex with compound 34 |
|
58
|
169
|
9gh0A |
Human kras4a (gmppnp) in complex with compound 32 |
|
59
|
169
|
9ggzA |
Human kras4a (gmppnp) in complex with compound 31 |
|
66
|
170
|
9bg4A |
Tri-complex of compound-2, kras g12v, and cypa |
|
50
|
164
|
9bgcC |
Tri-complex of daraxonrasib (rmc-6236), kras g12r, and cypa |
|
59
|
169
|
9bgcA |
Tri-complex of daraxonrasib (rmc-6236), kras g12r, and cypa |
|
50
|
165
|
9bg4C |
Tri-complex of compound-2, kras g12v, and cypa |
|
53
|
163
|
9bg5C |
Tri-complex of daraxonrasib (rmc-6236), kras g13d, and cypa |
|
61
|
168
|
9bg2A |
Tri-complex of compound-10, kras g12v, and cypa |
|
58
|
169
|
9bgbA |
Tri-complex of daraxonrasib (rmc-6236), kras q61h, and cypa |
|
58
|
170
|
9bgaA |
Tri-complex of daraxonrasib (rmc-6236), kras g12c, and cypa |
|
54
|
164
|
9bg6C |
Tri-complex of daraxonrasib (rmc-6236), kras g12v, and cypa |
|
59
|
168
|
9bg9A |
Tri-complex of daraxonrasib (rmc-6236), kras wt, and cypa |
|
52
|
163
|
9bgbC |
Tri-complex of daraxonrasib (rmc-6236), kras q61h, and cypa |
|
55
|
164
|
9bg9C |
Tri-complex of daraxonrasib (rmc-6236), kras wt, and cypa |
|
61
|
168
|
9bg6A |
Tri-complex of daraxonrasib (rmc-6236), kras g12v, and cypa |
|
54
|
163
|
9bgaC |
Tri-complex of daraxonrasib (rmc-6236), kras g12c, and cypa |
|
61
|
170
|
9bg5A |
Tri-complex of daraxonrasib (rmc-6236), kras g13d, and cypa |
|
51
|
163
|
9bg2C |
Tri-complex of compound-10, kras g12v, and cypa |
|
64
|
170
|
9e9hA |
Crystal structure of human kras g12c covalently bound to del triazine compound 5 |
|
62
|
170
|
8s8cA |
Structure of kras in complex with inhibitor mk-1084 |
|
62
|
170
|
9bfyA |
Tri-complex of compound-14, kras g12c, and cypa |
|
51
|
165
|
9bg1C |
Tri-complex of compound-3, kras g12v, and cypa |
|
51
|
165
|
9bfyC |
Tri-complex of compound-14, kras g12c, and cypa |
|
63
|
169
|
9bg1A |
Tri-complex of compound-3, kras g12v, and cypa |
|
62
|
170
|
9bi1A |
Crystal structure of gmppnp bound kras g12d in complex with cypa and rmc-7977 |
|
49
|
163
|
9bi1B |
Crystal structure of gmppnp bound kras g12d in complex with cypa and rmc-7977 |
|
65
|
169
|
8wb1A |
Crystal structure of small molecule kn2h covalently bound to k-ras(g12d) |
|
56
|
167
|
8vgqA |
Cryoem structure of gne-1952-alkylated kras g12c in complex with engineered conformationally rigid fab 2h11.4ds |
|
41
|
214
|
8vgqL |
Cryoem structure of gne-1952-alkylated kras g12c in complex with engineered conformationally rigid fab 2h11.4ds |
|
36
|
224
|
8vgqH |
Cryoem structure of gne-1952-alkylated kras g12c in complex with engineered conformationally rigid fab 2h11.4ds |
